Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has genetic confirmation of primary hyperoxaluria type 1 (PH1)~* Meets urinary oxalate excretion requirements~* If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days~Exclusion Criteria:~* If \<12 months old at screening, has an abnormally high serum creatinine~* If ≥12 months old at screening, has an estimated glomerular filtration rate (GFR) of ≤45 mL/min/1.73m\^2~* Clinical evidence of systemic oxalosis~* History of kidney or liver transplant

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Lumasiran (Type: EXPERIMENTAL): Lumasiran will be administered by subcutaneous (SC) injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).